Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Bioorg Med Chem. 2017 Dec 17;26(3):573–580. doi: 10.1016/j.bmc.2017.12.018

Fig. 4.

Fig. 4

3D bar graph depicting the dose-dependent hemolytic activity of azole derivatives 6-10 and VOR against mRBCs, which were treated and incubated for 1 h at 37 °C with each compound tested at concentrations ranging from 0.48-62.5 μg/mL. Triton X-100® (1% v/v) was used as a positive control (100% hemolysis, not shown).